Astria Therapeutics’ (ATXS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note published on Friday, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock.

ATXS has been the subject of a number of other research reports. Wedbush reaffirmed an outperform rating and set a $22.00 target price on shares of Astria Therapeutics in a research note on Friday. Jefferies Financial Group raised their target price on shares of Astria Therapeutics from $22.00 to $27.00 and gave the company a buy rating in a research note on Monday, March 25th.

Astria Therapeutics Stock Performance

ATXS traded down $0.44 on Friday, hitting $9.73. The company had a trading volume of 443,655 shares, compared to its average volume of 824,755. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The stock has a fifty day simple moving average of $12.16 and a 200-day simple moving average of $9.54.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, analysts anticipate that Astria Therapeutics will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ATXS. Vivo Capital LLC grew its position in Astria Therapeutics by 47.7% in the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock worth $19,067,000 after purchasing an additional 801,528 shares during the period. Affinity Asset Advisors LLC grew its position in Astria Therapeutics by 53.7% in the 3rd quarter. Affinity Asset Advisors LLC now owns 1,000,300 shares of the biotechnology company’s stock worth $7,462,000 after purchasing an additional 349,425 shares during the period. Jump Financial LLC bought a new stake in Astria Therapeutics in the 3rd quarter worth approximately $111,000. AJOVista LLC bought a new stake in Astria Therapeutics in the 4th quarter worth approximately $51,000. Finally, Vanguard Group Inc. grew its position in Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after purchasing an additional 480,184 shares during the period. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.